Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Obstet Gynecol. 2011 Jun;204(6 Suppl 1):S89-93. doi: 10.1016/j.ajog.2011.03.005. Epub 2011 Mar 9.

Pharmacokinetics of oseltamivir according to trimester of pregnancy.

Author information

  • 1University of Texas Southwestern Medical Center, Department of Obstetrics and Gynecology, Dallas, TX 75235-9032, USA.

Abstract

The purpose of this study was to determine pharmacokinetic parameters for oseltamivir in all trimesters of pregnancy. Thirty pregnant women, 10 per trimester, who were receiving oseltamivir phosphate (75 mg) were recruited to study first-dose pharmacokinetics. Plasma samples were obtained at 0, 0.5, 1, 2, 4, 8, and 12 hours after the first dose. Samples were analyzed for oseltamivir and oseltamivir carboxylate levels. With the use of a noncompartmental model, we estimated the area-under-the-curve, maximum concentration, time-to-maximum concentration, and half-life. There were no significant differences in the pharmacokinetics of oseltamivir by trimester, except for an increased half-life in the first trimester for oseltamivir phosphate and an increased maximum concentration in the third trimester for oseltamivir carboxylate. The levels of oseltamivir carboxylate that were observed were within the range that was needed to achieve inhibitory concentrations at 50% for pandemic H1N1. The pharmacokinetics of oseltamivir does not change significantly according to trimester of pregnancy.

Comment in

PMID:
21492824
PMCID:
PMC3111855
DOI:
10.1016/j.ajog.2011.03.005
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center